Ro5
Ro5 is a London-based biotechnology company focused on AI-enabled drug discovery, developing first-in-class small molecules, biologics, and cell therapies that target core aging mechanisms to extend healthy lifespan and treat age-related diseases.
- Company typePrivate
- Founded2018
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ro5 does
Ro5 is a biotechnology company operating in the AI-enabled drug discovery and longevity therapeutics space, with firmographic roots in London, UK (founded 2018, 11-50 employees, website Ro5.ai). The accompanying source material describes a clinical-stage drug development platform that integrates AI and data science tooling to design novel compounds and run adaptive clinical trials using patient stratification, biomarkers, and real-time analysis, with the stated objective of producing meaningful efficacy readouts at Phase 1.
The core product surface is a clinical pipeline of first-in-class medicines targeting core mechanisms of aging across three modalities — small molecules, biologics, and cell therapies. Five medicines were targeted for Phase I/II by 2025 and a PAI-1 inhibitor completed Phase 1 in February 2026. The adaptive clinical trial methodology is positioned as the principal efficiency lever. Distribution is conducted through traditional pharmaceutical development and regulatory pathways, targeting eventual commercialization via pharmaceutical partners or licensing arrangements rather than direct sales.
The business model is pre-commercial: no pricing is disclosed, no products are on the market, and no revenue figure is available in the source data. Capital is sourced via disclosed funding events in 2018-2020 (amounts undisclosed), leadership track record cited at $26B in prior M&A involvement and $30B in annual prior-role medicine sales, and active investor-relations outreach through international conferences (ARDD, Abu Dhabi Investment Forum, Singapore Week of Innovation & Technology, UBS Year Ahead). Geographic footprint includes a 2026 expansion into UAE's Masdar City Life Science Innovation Cluster. Customer engagement is B2B-pharma and licensing-oriented by design rather than volume revenue-driven.
Ro5 firmographics
Firmographics- Name
- Ro5
- Website
- https://Ro5.ai
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ro5 is a London-based biotechnology company focused on AI-enabled drug discovery, developing first-in-class small molecules, biologics, and cell therapies that target core aging mechanisms to extend healthy lifespan and treat age-related diseases.
- Ownership category
- akta.pro rank
Ro5 industry classification
Industry- Product category
- Longevity Therapeutics / Clinical-Stage Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where Ro5 is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Ro5 business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Distribution channels1 record
Marketing channels5 records
Ro5 product offering
Product offeringCore offering
Ro5 is a clinical-stage drug development company developing first-in-class medicines targeting core mechanisms of aging to extend healthy lifespan and prevent age-related diseases. The company operates an AI-enabled R&D platform that integrates data science tools to design novel compounds across multiple modalities (small molecules, biologics, cell therapies) and uses adaptive clinical trial design with biomarkers and patient stratification. Ro5 had five medicines in Phase I or II trials by 2025, with the PAI-1 Inhibitor completing Phase 1 in February 2026.
Product overview
Juvenescence is a clinical-stage drug development company offering a unified platform combining AI-enabled discovery and adaptive clinical trial design. Their core product is a pipeline of first-in-class medicines targeting core aging mechanisms, developed across multiple modalities (small molecules, biologics, cell therapies). The AI-enabled R&D platform supports compound design and development optimization, while adaptive clinical trial capabilities enable efficient Phase I/II execution. Together these form an integrated drug development ecosystem focused on extending healthy lifespan.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Five medicines expected in Phase I or II trials by 2025
- +1 more outcomes
Companies that use Ro5
Customer profileSegments1 record
Ideal customer profiles2 records
Ro5 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature3 records
Ro5 partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Eric Verdin / Buck Institute for Research on AgingcoreCollaborative research relationship with Eric Verdin from the Buck Institute for Research on Aging. Verdin presented data on Juvenescence's compound, indicating active co-development and validation of their therapeutic candidates.
- Relation TherapeuticscoreRelation Therapeutics announced a $1.7B strategic collaboration with Novartis for Atopic Diseases. Mentioned in Juvenescence news as a peer company in the longevity therapeutics space.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Ro5 competitors and assessment
Company assessmentDirect peers
- Unity Biotechnology: Clinical-stage biotech developing therapeutics that clear senescent cells to address age-related diseases. Closely comparable aging-mechanism target thesis and clinical-stage status to Ro5.
- Insitro: Machine-learning-driven drug discovery company developing therapies across multiple therapeutic areas using data science and biology. Comparable in approach (AI-enabled R&D compressing timelines) and stage (clinical-stage biotech).
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning to generate novel therapeutic candidates. Direct comparison to Ro5's AI-enabled R&D platform and clinical-stage pipeline model.
- BioAge Labs: Clinical-stage biotech developing medicines that target the biology of aging, with pipeline assets in metabolic and age-related disease. Directly comparable therapeutic area and clinical-stage profile to Ro5.
- Relation Therapeutics: AI-driven drug discovery company announced a $1.7B strategic collaboration with Novartis; explicitly named in the source data as a peer in the longevity therapeutics space. Direct overlap on AI-discovery and clinical translation.
- Insilico Medicine: AI-driven drug discovery company with clinical-stage assets in aging/age-related diseases, combining generative chemistry, target discovery, and clinical development. Closely overlaps Ro5's longevity focus plus AI-platform thesis.
Broad incumbents
- Schrödinger, Inc. Public computational drug discovery company offering physics-based platform plus internal pipeline. Comparable on AI/in silico R&D approach but operates more as a software-plus-pipeline platform than a single-asset longevity biotech.
- Altos Labs: Well-capitalized cell-rejuvenation biotech focused on restoring cell health to reverse disease and aging. Overlaps Ro5 on the aging/longevity therapeutic thesis and multi-modality (cell therapy) approach, with materially larger capital base.
- Calico Life Sciences: Alphabet-backed R&D biotech focused on aging biology and longevity. Comparable target space (core mechanisms of aging) with substantially deeper resources and incumbency in the longevity R&D category.
Emerging players
- Loyal for Dogs: Veterinary longevity biotech developing medicines to extend healthy lifespan in dogs, with FDA engagement on lifespan-extension endpoints. Indirect but thematic peer — same aging-mechanism thesis applied to a non-human indication as a regulatory path-finder.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Ro5 social profiles
Digital presenceRo5 financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ro5 leadership team
Management profileNumber of profiles
Profiles8 records
Ro5 funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ro5 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ro5
What does Ro5 do?
Ro5 is a clinical-stage drug development company developing first-in-class medicines targeting core mechanisms of aging to extend healthy lifespan and prevent age-related diseases. The company operates an AI-enabled R&D platform that integrates data science tools to design novel compounds across multiple modalities (small molecules, biologics, cell therapies) and uses adaptive clinical trial design with biomarkers and patient stratification. Ro5 had five medicines in Phase I or II trials by 2025, with the PAI-1 Inhibitor completing Phase 1 in February 2026.
Is Ro5 a public or private company?
Ro5 is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ro5 founded?
Ro5 was founded in 2018. It employs 11 to 50 people.
Where is Ro5 based?
Ro5 is headquartered in London, United Kingdom, in the Europe region.
Who are Ro5's main competitors?
Direct peers on record are Unity Biotechnology, Insitro, Recursion Pharmaceuticals, BioAge Labs, Relation Therapeutics and Insilico Medicine. Broad incumbents are Schrödinger, Inc., Altos Labs and Calico Life Sciences. Loyal for Dogs is listed as an emerging player.
Does Ro5 have an API?
No public API is recorded for Ro5.
What industry is Ro5 in?
Ro5's product category is Longevity Therapeutics / Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.